ODAIA Closes $15M Series C to Scale Pharma Commercial AI
ODAIA raised $15 million in Series C funding led by Monograph Capital, with Publicis Groupe's PHM joining as strategic investor and exclusive U.S. agency partner for its pharma commercial AI platform.
By Olivia Hart
3 min read

What's News
- ODAIA raised $15 million in Series C financing led by Monograph Capital
- PHM, Publicis Groupe's U.S. health media agency, took a strategic stake and became ODAIA's exclusive U.S. agency partner
- ODAIA was founded at the University of Toronto in 2018 and is headquartered in Toronto with a Boston office
- The platform claims to identify physicians whose patients may need a therapy months before formal diagnosis appears in data
- Six existing investors participated, including BDC Capital, Flint Capital and Wittington Ventures
ODAIA has raised $15 million in Series C financing to expand its predictive commercial intelligence platform for pharmaceutical companies. Monograph Capital led the round, with strategic participation from PHM, Publicis Groupe's U.S. health media agency. Existing investors BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures, and Wittington Ventures also participated.
The Toronto-based company, founded at the University of Toronto in 2018, will spend the money going deeper into its existing enterprise pharmaceutical accounts and continuing to develop the commercial intelligence technology. Alongside the financing, ODAIA signed a platform agreement making PHM its exclusive U.S. agency partner.
What problem does ODAIA claim to solve?
Pharmaceutical companies typically hold data in separate systems controlled by brand, marketing, analytics, and field-sales teams. That fragmentation produces different views of the same healthcare professional and makes it hard to determine which activities actually influence prescribing behavior.
ODAIA's answer is a unified layer combining patient, healthcare professional, digital engagement, and field-sales signals. The platform predicts patient journeys, flags missed prescription opportunities, prioritizes healthcare professionals, and recommends which channels and messages to use. The takeaway: one data layer, one view of the prescriber.
The product splits into three working parts. Brand teams set strategy in the Brand Strategy Studio, which converts that strategy into individual recommendations about whom to contact, when, on which channel, and with what message. Field Intelligence pushes prioritized call plans through the company's existing CRM system. Marketing Intelligence coordinates individualized professional journeys across digital and partner channels.
How strong are the predictive claims?
ODAIA says the platform can identify physicians whose patients may need a therapy months before a formal diagnosis appears in available data. The company itself concedes the limits: these are predictive recommendations, not clinical diagnoses, and performance depends on the relevant data and models. That caveat matters for buyers weighing ROI on a $15 million-backed platform.
The central proposition is reuse. ODAIA argues pharma companies should extend commercial AI across multiple products without building a new system for every brand or therapeutic area. Expansion, in the company's framing, becomes a configuration exercise: customers reuse the underlying infrastructure and adapt strategies and rules.
Each recommendation carries an explanation intended to help commercial and compliance teams understand why the system proposed an action. Users can also ask questions in plain language and receive completed analyses. The platform measures engagement and prescription lift, then feeds observed results into subsequent decisions.
What did the investors and CEO say?
CEO and co-founder Philip Poulidis framed the round around scaling rather than proving the concept. "Pharma has proven that AI works in commercial. The hard part now is scaling it. Most companies can show results on one brand, and every new brand or therapeutic area still costs another team and another build," he said. He added that the round "lets us go deeper with the enterprise customers we already serve and, with PHM, bring that infrastructure to more of the industry, faster."
Charles Conn, co-founder and partner at Monograph Capital, pointed to adoption as the differentiator. "We have watched the ODAIA team turn predictive AI into decisions that pharma brand and field teams act on every day," he said, citing the company's record with large and specialty pharma brands.
What changes with PHM?
The PHM partnership connects digital media signals with field-sales activity, letting customers coordinate healthcare professional engagement across both areas. ODAIA will keep selling directly to pharmaceutical companies, with its technology running alongside existing CRM systems, internal analytics models, and data infrastructure.
The strategic stake from a Publicis Groupe agency signals where ODAIA thinks distribution comes from next: media-side integration rather than pure software sales. The test ahead is whether configuration-based scaling holds up across portfolios or whether each new brand still demands custom work.
Source: pulse2.com
More from Olivia Hart
Show full bio
Staff writer covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.
2,378 articles